Objective： To systematically evaluate the clinical efficacy and safety of Potassium Dehydroandrographolide Succinate Injection （PDSI） in the treatment of child epidemic parotitis （EP）. Methods： Randomized contro...Objective： To systematically evaluate the clinical efficacy and safety of Potassium Dehydroandrographolide Succinate Injection （PDSI） in the treatment of child epidemic parotitis （EP）. Methods： Randomized controlled trials （RCTs） regarding PDSI in the treatment of child EP were searched in China National Knowledge Infrastructure, Wanfang Database, Chinese Biomedical Literature Database, PubMed, and Cochrane Library from inception to July 30, 2013. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and a meta- analysis was conducted with RevMan 5.2 software. Results： A total of 11 studies with 818 participants were included. The quality of the studies was generally low, among which only one study mentioned the random method. The meta-analysis indicated that PDSI was more effective than the conventional therapy with Western medicine for EP in the outcomes of the total effective rate [relative risk （RR）=1.23, 95% confidence interval （CI） [1.14, 1.33], P〈0.01], the time of temperature return to normal, the time of detumescence [mean difference （MD）=-2.10, 95% CI [-2.78, -1.41], P〈0.01], and the incidence of complications （RR=0.14, 95% CI [0.03, 0.72], P=0.02）. There were 6 adverse drug reactions （ADRs） in this systematic review, 2 of which were mainly represented rash and diarrhea in the experiment group, while another 4 ADRs occurred in the control group. Conclusions： Based on the systematic review, PDSI was effectiveness and relatively safety in the treatment of child EP. But further rigorously designed trials are warranted to determine its effectiveness.展开更多
基金Supported by the National Science and Technology Support Program of China(No.2006BAI21B11)the Scientific Research Innovation Team Project of Beijing University of Chinese Medicine(No.2011-CXTD-14)
文摘Objective： To systematically evaluate the clinical efficacy and safety of Potassium Dehydroandrographolide Succinate Injection （PDSI） in the treatment of child epidemic parotitis （EP）. Methods： Randomized controlled trials （RCTs） regarding PDSI in the treatment of child EP were searched in China National Knowledge Infrastructure, Wanfang Database, Chinese Biomedical Literature Database, PubMed, and Cochrane Library from inception to July 30, 2013. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and a meta- analysis was conducted with RevMan 5.2 software. Results： A total of 11 studies with 818 participants were included. The quality of the studies was generally low, among which only one study mentioned the random method. The meta-analysis indicated that PDSI was more effective than the conventional therapy with Western medicine for EP in the outcomes of the total effective rate [relative risk （RR）=1.23, 95% confidence interval （CI） [1.14, 1.33], P〈0.01], the time of temperature return to normal, the time of detumescence [mean difference （MD）=-2.10, 95% CI [-2.78, -1.41], P〈0.01], and the incidence of complications （RR=0.14, 95% CI [0.03, 0.72], P=0.02）. There were 6 adverse drug reactions （ADRs） in this systematic review, 2 of which were mainly represented rash and diarrhea in the experiment group, while another 4 ADRs occurred in the control group. Conclusions： Based on the systematic review, PDSI was effectiveness and relatively safety in the treatment of child EP. But further rigorously designed trials are warranted to determine its effectiveness.
文摘目的:系统评价炎琥宁注射剂治疗流行性腮腺炎的疗效,探索省增补基本药物循证评价的有效方式,为新版基本药物目录遴选提供参考。方法:计算机检索Pub Med、中国期刊全文数据库(CJFD)、万方数据库、中文科技期刊数据库(VIP),收集炎琥宁注射剂单用或者联合其他阳性药物(试验组)对比其他阳性药物(对照组)治疗流行性腮腺炎的随机对照试验(RCT),采用改良的Jadad评分量表评价质量后,提取有效数据采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入26项RCT,合计2 613例患者。Meta分析结果显示,试验组患者总有效率[OR=5.28,95%CI(3.92,7.11),P<0.001]显著高于对照组,退热时间[MD=-1.97,95%CI(-2.83,-1.12),P<0.001]、肿胀消退时间[MD=-2.05,95%CI(-2.53,-1.58),P<0.001]、疼痛消失时间[MD=-1.39,95%CI(-2.02,-0.75),P<0.001]均显著短于对照组,差异均有统计学意义。结论:炎琥宁注射剂治疗流行性腮腺炎疗效较好,可显著缩短患者退热时间、肿胀消退时间和疼痛消失时间。
